Roche/Spark Deal Clears FTC In A Sigh Of Relief For Pharma Dealmakers
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.
You may also be interested in...
Biosimilar competitors to Avastin, Herceptin and Rituxan and headwinds from COVID-19 are expected to have a CHF4.7bn negative impact in 2020, higher than the CHF4bn previously projected.
Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.
BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.